Valiant LaboratoriesNSE:VALIANTLAB -0.58%52 Return-on-Tangible-Asset is 1.52% as of Mar. 2026, which is 79% below its 10-year median of 7.41. GuruFocus rates NSE:VALIANTLAB with a GF Score™ of 52/100 and a GF Value™ of ₹102.49 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 1,005 Drug Manufacturers companies, Valiant Laboratories ranks worse than 64.88% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Valiant Laboratories's annualizedNet Income for the quarter that ended in Mar. 2026 was ₹70 Mil. Valiant Laboratories's average total tangible assets for the quarter that ended in Mar. 2026 was ₹4,639 Mil. Therefore, Valiant Laboratories's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 1.52%.
The historical rank and industry rank for Valiant Laboratories's Return-on-Tangible-Asset or its related term are showing as below:
NSE:VALIANTLAB'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -0.76 Med: 7.41 Max: 28.78
Current: -0.76
During the past 6 years, Valiant Laboratories's highest Return-on-Tangible-Asset was 28.78%. The lowest was -0.76%. And the median was 7.41%.
NSE:VALIANTLAB's Return-on-Tangible-Asset is ranked worse than 64.88% of 1005
companies
in the Drug Manufacturers industry
Industry Median: 3.16
vs NSE:VALIANTLAB: -0.76
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Valiant Laboratories Return-on-Tangible-Asset Related Terms
Valiant Laboratories Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Valiant Laboratories's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:VALIANTLAB vs ZTS, UTHR: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Valiant Laboratories's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Valiant Laboratories Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Valiant Laboratories's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Valiant Laboratories's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 1.52% mean?
Valiant Laboratories (NSE:VALIANTLAB) has a Return-on-Tangible-Asset of 1.52% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Valiant Laboratories and its competitors. This is 79% below median its historical median of 7.41. According to the industry distribution chart, Valiant Laboratories ranks #652 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 64.9%.
Is Valiant Laboratories' Return-on-Tangible-Asset too high?
Valiant Laboratories' current Return-on-Tangible-Asset of 1.52% is 79% below median its 10-year median of 7.41. The Drug Manufacturers industry median Return-on-Tangible-Asset is 3.16. Valiant Laboratories' value of 1.52% is 51.9% below this industry median. Based on the distribution chart, Valiant Laboratories ranks #652 out of 1005 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Valiant Laboratories has a GF Score™ of 52/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Valiant Laboratories' Return-on-Tangible-Asset compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Valiant Laboratories ranks #652 out of 1005 companies for Return-on-Tangible-Asset. This places Valiant Laboratories in the lower half of its industry. The industry median Return-on-Tangible-Asset is 3.16. Valiant Laboratories' value of 1.52% is 51.9% below this benchmark. While the company's 10-year median is 7.41 vs. the industry median of 3.16, Valiant Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 3.16, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Valiant Laboratories's current Return-on-Tangible-Asset of 1.52% is 51.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Valiant Laboratories and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 3.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Valiant Laboratories's current Return-on-Tangible-Asset is 1.52%, which is 79% below median its own 10-year median of 7.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Valiant Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Valiant Laboratories (NSE:VALIANTLAB) is currently considered Possible Value Trap. The stock's GF Value™ is ₹102.49, compared to a current price of ₹63.86 — trading 37.7% below its estimated fair value. The current Return-on-Tangible-Asset is 1.52%, which is 79% below median its 10-year median of 7.41 and 51.9% below the Drug Manufacturers industry median of 3.16. Valiant Laboratories' overall GF Score™ is 52/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Valiant Laboratories (NSE:VALIANTLAB), the current Return-on-Tangible-Asset is 1.52% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Valiant Laboratories (NSE:VALIANTLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Valiant Laboratories stock appears to be undervalued.
The current stock price of ₹63.86 is trading 37.7% below its estimated GF Value™ of ₹102.49.
GuruFocus considers Valiant Laboratories to be Possible Value Trap.
Key valuation signals for NSE:VALIANTLAB:
Return-on-Tangible-Asset: 1.52% (79% below median its 10-year median of 7.41)
GF Value™: ₹102.49 vs. price of ₹63.86 (37.7% below fair value)
Industry Position: 51.9% below the Drug Manufacturers median (#652 of 1005)
No single metric tells the full story. See the NSE:VALIANTLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Valiant Laboratories Ltd is an Active Pharmaceutical Ingredient (API)/Bulk Drug manufacturing company with having focus on manufacturing Paracetamol. Paracetamol is one of the widely used analgesics globally and is recommended as the first-line therapy in pain conditions by the World Health Organization. Paracetamol has several applications such as usage in the treatment of headaches, muscle aches, arthritis, backaches, toothaches, colds, and fever. It manufactures Paracetamol in various grades such as IP/BP/EP/USP, as per the pharmacopeia requirements of its customers.
52GF Score
Get the complete analysis for NSE:VALIANTLAB
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:VALIANTLAB has been successfully added to your 
